Pulmatrix (NSDQ:PULM) said today that the FDA approved a Phase II trial of the company’s inhaled formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis in people with asthma.
The Lexington, Mass.-based company plans to kick off the trial in the first half of 2019, with top-line data expected in the second quarter of 2020.
Get the full story at our sister site, Drug Delivery Business News.